Achieving Operational Excellence in Pharma & Biotech

With the pharmaceutical industry currently going through major transformation, improving productivity and reducing costs by implementing Operational Excellence is increasingly important for business success. Pharma and biotech companies can benefit significantly by adapting the experience of other industries who have implemented similar tools and methods. Process Insight understand the business challenges, have deep experience and have relevant answers. Whether you are looking for a solution to specific problem or the design and delivery of a full Opex programme this paper will outline how you can cut through the potential complexity in order to identify a pragmatic & practical way forward.

Spotlight

NovaBay Pharmaceuticals

NovaBay Pharmaceuticals $NBY is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. NovaBay has two distinct product categories: the NEUTROX™ family of products, led by AVENOVA™ for the eye care market, NEUTROPHASE® for wound care, and CELLERX™ for the dermatology market; and AGANOCIDE® compounds, led by AURICLOSENE™. NovaBay is commercializing AVENOVA, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. These difficult-to-manage conditions affect approximately 30 million Americans, with an annual market potential that NovaBay estimates at $500 million.

OTHER WHITEPAPERS
news image

Reimagining the pharma landscape with design thinking

whitePaper | July 29, 2021

As pharma companies strive for increased commercial success the customer-centric focus can get lost in the adoption of new commercial endeavours. As a result, many have been looking toward the world of design as a way of enhancing their customer engagement and accelerating their position in the market.

Read More
news image

Pharma 2020: Marketing the future. Which path will you take?

whitePaper | August 8, 2021

If Pharma is to create a new marketing and sales model that is fit for 2020, it will have to begin by analysing its own value chain to identify opportunities for working more closely with healthcare payers and providers. It will, for example, have to collaborate much more closely with payers (be they governments, health insurers, employers or patients) to ensure that it develops medicines which have real social and economic value.

Read More
news image

How IPD Can Deliver for Life Sciences

whitePaper | January 1, 2020

Life sciences is facing a number of disruptors: novel cell and gene therapies that will revolutionize manufacturing, drug delivery and pricing models; a battle for the best and brightest talent; political and public pressure on the price of medication as well as the implications of the fourth industrial revolution. These factors combine to make investment decisions more challenging. With life sciences firms placing an increasing focus on the most efficient use of capital and shorter delivery times, project delivery providers are striving to come up with leaner and more innovative strategies and solutions to meet these needs. Integrated Project Delivery (IPD) is one such strategy.

Read More
news image

WILL PHARMA COMMIT TO DELIVERING AFFORDABLE THERAPEUTICS AGAINST COVID-19?

whitePaper | April 8, 2020

EPHA is a change agent – Europe’s leading NGO alliance advocating for better health. We are a dynamic member-led organisation, made up of public health civil society, patient groups, health professionals, and disease groups working together to improve health and strengthen the voice of public health in Europe.

Read More
news image

Effects Of X-Ray Inspection On Pharmaceutical Products

whitePaper | December 12, 2019

X-ray inspection of pharmaceutical products and over-the-counter (OTC) medications are steadily increasing in use as pharmaceutical manufacturers worldwide strive to safeguard their brand reputations, protect consumers' welfare and comply with national and international regulations and legislation.

Read More
news image

Deck 7 Webinars and Virtual Events

whitePaper | January 1, 2020

If you recognize some of these challenges, download the Deck 7 Webinar & Virtual Events overview to see how we make it easy for busy marketers to run highly successful webinars and virtual events....

Read More

Spotlight

NovaBay Pharmaceuticals

NovaBay Pharmaceuticals $NBY is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. NovaBay has two distinct product categories: the NEUTROX™ family of products, led by AVENOVA™ for the eye care market, NEUTROPHASE® for wound care, and CELLERX™ for the dermatology market; and AGANOCIDE® compounds, led by AURICLOSENE™. NovaBay is commercializing AVENOVA, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. These difficult-to-manage conditions affect approximately 30 million Americans, with an annual market potential that NovaBay estimates at $500 million.

Events